Liberum Capital reiterated their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report sent to investors on Tuesday. Liberum Capital currently has a GBX 1,900 ($24.80) price target on the stock.

Other equities analysts have also issued research reports about the company. Beaufort Securities reaffirmed a buy rating on shares of GlaxoSmithKline plc in a research note on Tuesday, August 2nd. Jefferies Group reaffirmed a buy rating and issued a GBX 2,000 ($26.11) price target on shares of GlaxoSmithKline plc in a research note on Friday, July 29th. BNP Paribas reaffirmed a neutral rating on shares of GlaxoSmithKline plc in a research note on Friday, July 29th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of GlaxoSmithKline plc in a research note on Thursday, July 28th. Finally, Deutsche Bank AG reaffirmed a hold rating and issued a GBX 1,700 ($22.19) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 28th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have assigned a buy rating to the stock. GlaxoSmithKline plc presently has an average rating of Hold and a consensus price target of GBX 1,676.44 ($21.88).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1634.50 on Tuesday. The firm has a 50-day moving average of GBX 1,655.81 and a 200 day moving average of GBX 1,530.22. The firm’s market capitalization is GBX 79.45 billion. GlaxoSmithKline plc has a 52 week low of GBX 1,227.50 and a 52 week high of GBX 1,716.50.

The firm also recently disclosed a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be given a GBX 19 ($0.25) dividend. This represents a yield of 1.12%. The ex-dividend date is Thursday, August 11th.

In related news, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43). Also, insider Cartwright,Stacey acquired 461 shares of GlaxoSmithKline plc stock in a transaction that occurred on Friday, July 1st. The stock was bought at an average price of GBX 1,559 ($20.35) per share, with a total value of £7,186.99 ($9,381.27).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.